Trial emulation shows the effectiveness of the COVID-19 vaccine in improving long COVID symptoms univ_spn COVID19 SARSCoV2 LongCOVID Vaccine Effectiveness
Background It is well-recognized that vaccination against severe acute respiratory syndrome coronavirus 2 effectively reduces the risk of hospitalization, mortality, and re-infection. However, studies have not adequately investigated its effects in individuals previously infected with SARS-CoV-2 and living with post-acute sequelae of SARS-CoV-2 or long COVID.
Per the United Kingdom Office for National Statistics, 90% of long COVID patients experience symptoms up to one year after the initial infection, and 67% do not resume pre-COVID work efficiency. Thus, reports that COVID-19 vaccines improve long COVID symptoms are encouraging. A non-peer-reviewed study conducted among 900 patients in the UK found that vaccination reduced the likelihood of long COVID symptoms; however, they had no control group for comparison.
Results Only 910 enrollees in the ComPaRe long COVID e-cohort provided their vaccination status, of which 733 were women, and their median age was 47 years. The period between symptom onset and baseline was 10.7 months. Among 455 vaccinated individuals, 359, 48, 47, and one patient received BNT162b2, ChAdOx1, mRNA-1273, and Ad26.COV2.S vaccines, respectively. All 455 patients in the control group had similar characteristics as individuals in the vaccinated group.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Scot who was paralysed in car crash hopes Glasgow clinical trial can revolutionise spinal treatmentScott Nicolson, 30, lost all sensation below his shoulders after he was paralysed following a serious car crash in October 2020 now he is taking part in a clinical trial in Glasgow.
Read more »
Family of Scot left disabled after breaking back in crash raising cash for trialScott Nicolson was badly injured in a car crash on Shetland.
Read more »
Man to stand trial charged with murder of nine-year-old Olivia Pratt-KorbelThomas Cashman, 34, goes on trial in Manchester today - he denies murdering the schoolgirl who was shot dead in her home in Liverpool
Read more »
Temperature-stable tuberculosis vaccine safe, prompts immune response in first-in-human trialA clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. The Phase 1 trial was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. A non-temperature stable form of the candidate previously had been tested in several clinical trials. However, this was the first clinical trial of any subunit TB vaccine candidate in a temperature-stable (thermostable) form. Results are published in Nature Communications.
Read more »
Olivia Pratt-Korbel murder trial updates as man accused of killing nine-year-oldOlivia Pratt-Korbel murder trial updates as man accused of killing nine-year-old - latest from Manchester Crown Court
Read more »
Olivia Pratt-Korbel's family arrive at Manchester court for murder trialOlivia Pratt-Korbel's family arrive at Manchester court for trial of man accused of murdering girl
Read more »